請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/10578
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 王榮德(Jung-Der Wang) | |
dc.contributor.author | Chien-Tung Wu | en |
dc.contributor.author | 吳建東 | zh_TW |
dc.date.accessioned | 2021-05-20T21:40:51Z | - |
dc.date.available | 2012-09-13 | |
dc.date.available | 2021-05-20T21:40:51Z | - |
dc.date.copyright | 2010-09-13 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-12 | |
dc.identifier.citation | 1.Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A. Jun 11 1996;93(12):5925-5930.
2.Degnim AC, Visscher DW, Berman HK, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. Jul 1 2007;25(19):2671-2677. 3.van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. Sep 15 2000;152(6):514-527. 4.Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA. Jul 12 2006;296(2):193-201. 5.Maruti SS, Willett WC, Feskanich D, Rosner B, Colditz GA. A prospective study of age-specific physical activity and premenopausal breast cancer. J Natl Cancer Inst. May 21 2008;100(10):728-737. 6.Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA. Nov 7 2001;286(17):2143-2151. 7.Allen NE, Beral V, Casabonne D, et al. Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst. Mar 4 2009;101(5):296-305. 8.Thiebaut AC, Kipnis V, Chang SC, et al. Dietary fat and postmenopausal invasive breast cancer in the National Institutes of Health-AARP Diet and Health Study cohort. J Natl Cancer Inst. Mar 21 2007;99(6):451-462. 9.Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. Feb 8 2006;295(6):629-642. 10.Hsieh CC, Trichopoulos D, Katsouyanni K, Yuasa S. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer. Nov 15 1990;46(5):796-800. 11.Hankinson SE, Colditz GA, Manson JE, et al. A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States). Cancer Causes Control. Jan 1997;8(1):65-72. 12.Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. Jun 27 2002;346(26):2025-2032. 13.Silvera SA, Miller AB, Rohan TE. Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study. Cancer Causes Control. Nov 2005;16(9):1059-1063. 14.Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. Jul 17 2002;288(3):321-333. 15.Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. Apr 12 2006;295(14):1647-1657. 16.Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. Oct 1 2003;290(13):1739-1748. 17.Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. May 28 2003;289(20):2651-2662. 18.Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. Mar 5 2008;299(9):1036-1045. 19.Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet. Sep 18 2009:1243-1251. 20.Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. Aug 9 2003;362(9382):419-427. 21.Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. Apr 30-May 6 2005;365(9470):1543-1551. 22.Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. May 19 2007;369(9574):1703-1710. 23.Liu B, Beral V, Balkwill A, Green J, Sweetland S, Reeves G. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ. 2008;337:a386. 24.van de Weijer PH. Risks of hormone therapy in the 50-59 year age group. Maturitas. May 20 2008;60(1):59-64. 25.Verkooijen HM, Bouchardy C, Vinh-Hung V, Rapiti E, Hartman M. The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. Maturitas. Oct 20 2009;64(2):80-85. 26.Kuo DJ, Lee YC, Huang WF. Hormone therapy use and prescription durations of menopausal women in Taiwan: a 5 years' National Cohort study. Maturitas. Nov 20 2007;58(3):259-268. 27.Huang WF, Tsai YW, Hsiao FY, Liu WC. Changes of the prescription of hormone therapy in menopausal women: an observational study in Taiwan. BMC Public Health. 2007;7:56. 28.Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007;9(3):R28. 29.Kim K, Zang R, Choi SC, Ryu SY, Kim JW. Current status of gynecological cancer in China. J Gynecol Oncol. Jun 2009;20(2):72-76. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/10578 | - |
dc.description.abstract | 研究目的:
由於荷爾蒙療法對於潮熱及陰道乾澀的療效顯著,因此,美國在1960年代以後女性使用此療法極為盛行,但由於其用藥安全的疑慮,美國國家衛生研究院自從在1993年開始,陸續進行許多大規模的研究之後,到目前為止,使用雌激素合併黃體素對於乳癌的風險已被確定,但單純使用雌激素對於乳癌的風險仍然不明。在此同時,許多研究諸如英國MWS也已看到雌激素合併黃體素或是單純使用雌激素具有相當的風險,因此本研究希望能透過健保資料庫進一步釐清兩種荷爾蒙使用方式對於乳癌風險的差別。 本研究藉由健保資料庫描述雌激素的醫療利用情形,計算各類雌激素製劑的使用型態,進而評估與乳癌發生風險的相關性。 研究方法: 本研究主要以全民健康保險研究資料庫中1997-2008共12年的100萬健保抽樣歸人檔之婦女所有就醫記錄檔為母群體,經過扣除非女性498,838人,未滿20歲193,511人,超過79歲2,242,1998年以前曾發生癌症,或是乳癌前曾發生過其他癌症的1,926人,以及曾使用過乳癌用藥的850人,我們得到305,633人,再扣掉曾使用中藥的239,910人,最後,我們得到未曾使用中藥而曾使用荷爾蒙的25,671人為研究組,而未使用中藥也未使用荷爾蒙的40,052人為對照組,共計65,723位女性。然後我們以乳癌的發生為結果,分別計算不同女性荷爾蒙使用狀況下的風險比,以Cox model作回歸分析。 結果與討論: 相對於未使用中藥與女性荷爾蒙兩者的女性,停用荷爾蒙越久,其發生乳癌的風險就越低,在最後一年並用雌激素與黃體素者風險最高,風險比8.71(95%CI, 5.50-13.82),而僅使用雌激素的風險則較低,風險比為2.04(95%CI, 1.37-3.06)。停經後的女性仍有相類似的情況,最後一年並用雌激素與黃體素者的風險比為54.05 (95%CI, 28.94-100.93),而僅使用雌激素的風險比為3.01(95%CI, 1.32-6.87)。 結論: 本研究顯示,在1997到2008年的健保資料庫中,乳癌的發生風險,合併雌激素與黃體素處方有較僅使用雌激素製劑處方的婦女較高的風險,本研究顯示在55至79歲婦女使用僅含雌激素處方,仍有乳癌發生風險較高的安全疑慮。 | zh_TW |
dc.description.abstract | Aim:
Proven benefits of hormone replacement therapy (HRT) include relief of vasomotor symptoms and vaginal atrophy and prevention and treatment of osteoporosis. Therefore, HRT given as either unopposed estrogen replacement therapy (ERT) or estrogen plus progestin gained widespread popularity in the United States since 1960s. The Women's Health Initiative (WHI) trial of estrogen plus progestin vs. placebo was stopped early, after a mean 5.6 years of follow-up, because the overall health risks of hormone therapy exceeded its benefits. The Women’s Health Initiative Estrogen-Alone trial comparing conjugated equine estrogens with placebo was stopped early because of an increased stroke incidence and no reduction in risk of coronary heart disease. Preliminary results suggesting possible reduction in breast cancers which are not consistent with the findings of some observational studies warranted more detailed analysis. Because female hormones are reimbursed under the National Health Insurance program in Taiwan, it is possible to access and analyze nationwide data for these drugs. The purposes of this study were to estimate the effect of hormone replacement therapies (HRT) on the risk of incidence of breast cancer in women in Taiwan. Method: We used the 1,000,000 random sampling from the National Health Insurance Research Database (NHIRD) during 1997-2008 in our study. After excluded male, aged fewer than 20 and above 80, women who had cancer or had breast cancer medication previously, we had totally 305,633 women. In order to avoid the effect of Chinese herbal product, we also excluded 239,910 women who ever used it. At last, we recruited 65,723 who used estrogen alone, progesterone alone, estrogen plus progesterone and women used neither hormone nor Chinese herbal products were recruited into our study. The risk of hormone utilization was estimated by Cox model. Results & Discussion: Among 2,798 women who have used solely estrogen plus progestin during study period, 45 newly breast cancer were diagnosed after taking estrogen plus progestin. Comparing to 76 newly diagnosed breast cancers among 5,156 women who have used unopposed estrogen during the same study period, significant higher estimated hazard rate of estrogen plus progestin users was found in present study. Women used combination of estrogen and progesterone in the last year were under the higher risk (HR: 8.71, 95%CI, 5.50-13.82) than estrogen-only (HR: 2.04, 95%CI, 1.37-3.06). Of all breast cancer women among estrogen plus progestin users, 23 (51%) of them were diagnosed at age between 55 and 79 years. Further analyses found that the significant association between the current use of estrogen plus progestin and the risk of breast cancer incidence among women aged between either 20 to 79 years or 55 to 79 years who were less likely to use oral pills. The data also demonstrated that discontinued exposure to estrogen plus progestin for half a year will significant decrease the risk of breast cancer among both women of reproductive age and 55 to 79 years of age, and the trend for lower risk was observed for women discontinuing exposure for longer period. This observation suggests a role for cumulative exposure of estrogen plus progestin on breast cancer risk. The positive association between ERT use and the increase of breast cancer occurrence was also found. In addition, the trends across categories of usage status appeared to be the longer discontinued ERT use before breast cancer was diagnosed are significant associated with the lower risk of breast cancer, indicating a positive relationship exists between excessive exposure of unopposed estrogen and breast cancer. The results of present study strongly support an added impact of progestin on the breast cancer risk associated with ERT. Various type of HRT were prescribed either following the updated guidelines on the use of HRT or after careful clinical judgment based on well informed about the potential benefit and perceived risks of HRT by well-trained qualified physicians resulting in the clinical performance that women use combined estrogen-progestin had significant higher breast cancer incidence than those use unopposed estrogen. Conclusions: This study provides strong evidence that the addition of a progestin to HRT enhances markedly the risk of breast cancer relative to estrogen use alone in Taiwan. These findings have important implications for the risk–benefit equation for HRT in women using estrogen plus progestin. | en |
dc.description.provenance | Made available in DSpace on 2021-05-20T21:40:51Z (GMT). No. of bitstreams: 1 ntu-99-R95841009-1.pdf: 635804 bytes, checksum: 24322e5e5a19702692cc2d32005e26fe (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 中文摘要 i
英文摘要 iii 壹、前言 1 一、雌激素與乳癌 1 1.雌激素 1 2.雌激素接受器 1 3.雌激素作用機轉 1 4.雌激素的藥物動力學 2 5.乳癌的危險因子 2 二、雌激素不良反映的文獻回顧 3 貳、材料與方法 6 一、資料來源 6 1.資料庫之建立 6 2.婦女研究族群之選定 6 3.雌激素和黃體素藥證之來源 9 4.中藥藥證之來源 9 二、變項的確定與定義 9 1.雌激素和黃體素使用的定義 9 2.中藥使用的定義 10 3.診斷代碼之定義 10 4.乳癌的定義 10 三、統計分析方法 11 參、結果 12 一、乳癌發生的概況比較 12 二、研究族群的基本資料 15 三、未使用科學中藥也未使用女性荷爾蒙的風險比較 17 四、女性荷爾蒙的風險比較 18 五、停經後女性荷爾蒙的風險比較 20 肆、討論 22 伍、結論 26 陸、致謝 26 柒、參考文獻 27 捌、附錄 30 | |
dc.language.iso | zh-TW | |
dc.title | 女性荷爾蒙療法與乳癌發生風險之相關性研究:台灣健保資料庫之分析 | zh_TW |
dc.title | Risk of Hormone Replacement Therapy on breast cancer: Analysis of National Health Insurance Research Database | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 賴榮年(Jung-Nien Lai),陳保中(Pau-Chung Chen),周松男(Song-Nan Chow),黃俊升(Chiun-Sheng Huang) | |
dc.subject.keyword | 女性荷爾蒙,雌激素,乳癌,藥物流行病學,健保資料庫, | zh_TW |
dc.subject.keyword | estrogen,breast cancer,insurance claims database,pharmacoepidemiology,National Health Insurance Research Database, | en |
dc.relation.page | 54 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2010-08-13 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 職業醫學與工業衛生研究所 | zh_TW |
顯示於系所單位: | 職業醫學與工業衛生研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf | 620.9 kB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。